Kust D - Search Results

1

Cytokeratin 20 positive cells in blood of colorectal cancer patients as an unfavorable prognostic marker.

Kust D, Šamija I, Kirac I, Radić J, Kovačević D, Kusić Z. Kust D, et al. Acta Clin Belg. 2016 Aug;71(4):235-43. doi: 10.1080/17843286.2016.1177264. Epub 2016 May 4. Acta Clin Belg. 2016. PMID: 27144776

2

Clinical and prognostic significance of anisocytosis measured as a red cell distribution width in patients with colorectal cancer.

Kust D, Lucijanic M, Urch K, Samija I, Celap I, Kruljac I, Prpic M, Lucijanic I, Matesa N, Bolanca A. Kust D, et al. QJM. 2017 Jun 1;110(6):361-367. doi: 10.1093/qjmed/hcw223. QJM. 2017. PMID: 28069908

3

Use of Alternative and Complementary Medicine in Patients with Malignant Diseases in High-Volume Cancer Center and Future Aspects.

Kust D, Šamija I, Marić-Brozić J, Svetec B, Miletić M, Mamić G, Bolanča A, Kusić Z, Fröbe A. Kust D, et al. Acta Clin Croat. 2016 Dec;55(4):585-592. doi: 10.20471/acc.2016.55.04.08. Acta Clin Croat. 2016. PMID: 29117649

4

DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131).

Prpić M, Franceschi M, Jukić T, Kust D, Dabelić N, Varjačić T, Lucijanić M, Bolanča A, Kusić Z. Prpić M, et al. Among authors: kust d. Acta Clin Croat. 2019 Mar;58(1):119-127. doi: 10.20471/acc.2019.58.01.16. Acta Clin Croat. 2019. PMID: 31363334 Free PMC article.

5

Malignancy risk with atypia of undetermined significance finding on thyroid nodule FNA: clinical experience from a tertiary institution.

Staničić J, Kust D, Mateša N, Kusić Z. Staničić J, et al. Among authors: kust d. Acta Clin Croat. 2019 Jun;58(2):333-336. doi: 10.20471/acc.2019.58.02.17. Acta Clin Croat. 2019. PMID: 31819330 Free PMC article.

6

Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.

Kust D, Prpić M, Murgić J, Jazvić M, Jakšić B, Krilić D, Bolanča A, Kusić Z. Kust D, et al. Anticancer Res. 2014 Jun;34(6):3177-84. Anticancer Res. 2014. PMID: 24922691

7

Clinical Significance of Multinodularity in Patients with Papillary Thyroid Carcinoma.

Kust D, Mateša N, Kusić Z. Kust D, et al. Anticancer Res. 2015 Nov;35(11):6335-9. Anticancer Res. 2015. PMID: 26504073

8

Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.

Prpic M, Kruljac I, Kust D, Kirigin LS, Jukic T, Dabelic N, Bolanca A, Kusic Z. Prpic M, et al. Among authors: kust d. Endocrine. 2016 Jun;52(3):602-8. doi: 10.1007/s12020-015-0846-9. Epub 2016 Jan 6. Endocrine. 2016. PMID: 26732041

9

Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patients.

Prpic M, Kust D, Kruljac I, Kirigin LS, Jukic T, Dabelic N, Bolanca A, Kusic Z. Prpic M, et al. Among authors: kust d. Head Neck. 2017 Jan;39(1):109-115. doi: 10.1002/hed.24550. Epub 2016 Jul 26. Head Neck. 2017. PMID: 27459351

10

Sunitinib-induced thyrotoxicosis - a not so rare entity.

Jazvić M, Prpić M, Jukić T, Murgić J, Jakšić B, Kust D, Prgomet A, Bolanča A, Kusić Z. Jazvić M, et al. Among authors: kust d. Anticancer Res. 2015 Jan;35(1):481-5. Anticancer Res. 2015. PMID: 25550591

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters